Dr. Roy Altman Joins BioChemics, Inc. Scientific Advisory Board to Advise on Clinical Development of Targeted Osteoarthritis Therapy
5/7/2008 11:15:22 AM
DANVERS, Mass.--(BUSINESS WIRE)--BioChemics, Inc., a company “pioneering transdermal drug delivery,” is pleased to announce that Dr. Roy D. Altman, Professor of Medicine, Division of Rheumatology and Immunology at the University of California, Los Angeles and Past President of the Osteoarthritis Research Society International has elected to serve as a member of the Company’s Scientific Advisory Board (SAB). Dr. Altman will be providing strategic input into the clinical development of the company’s targeted, topical, non steroidal anti-inflammatory (NSAID) product to treat osteoarthritis.
comments powered by